Ipsen hands back Parkinson's drug rights to Santhera

French drugmaker Ipsen ($IPN) has a game plan for developing new drugs, and Santhera's ($SANN) Parkinson's disease treatment fipamezole didn't make the cut. Switzerland-based Santhera said that it has regained worldwide rights to the experimental drug from Ipsen and is now looking for a new partner for the program, which is set to enter late-stage studies for treating dyskinesia in Parkinson's patients, Reuters reported. In return for handing back rights to the drug to Santhera for markets outside North America and Japan, Ipsen is expected to get a cut of potential milestones and royalties related to fipamezole. Article

Suggested Articles

In this week's EuroBiotech Report, AstraZeneca plans 2020 lupus filing, Roche's SMA trial hits endpoint and Kiadis cuts staff in R&D pivot.

In our EuroBiotech roundup this week, NEC and Vaximm ink cancer vaccine pact, Compugen posts cancer data and Lunac raises cash.

Biotech venture fund ATAI Life Sciences has partnered with artificial intelligence drug discovery specialist Cyclica to form a new JV.